Leaky Gut Biomarkers Can Predict Heart Disease, Diabetes, and Stroke Risk

Your gut lining is a selective barrier, and when it fails, the consequences reach far beyond digestion. A review published in the Journal of Gastroenterology and Liver Diseases by CS Cătană, MM Marta, D Popa, EC Crăciun, and colleagues maps the growing body of evidence connecting intestinal hyperpermeability, commonly called leaky gut, to metabolic syndrome, type 2 diabetes, coronary artery disease, and stroke. What makes the review particularly useful is its focus on blood-based and urine-based biomarkers: measurable signals that could eventually replace cumbersome lab tests and flag cardiometabolic risk years before a clinical event.

LBP, sCD14, and Zonulin as Measurable Signals of a Leaky Gut

When the gut barrier breaks down, lipopolysaccharide (LPS), a fragment of the outer wall of Gram-negative bacteria, slips into the bloodstream. The body responds by activating a signaling cascade through LPS-binding protein (LBP), soluble CD14 (sCD14), and Toll-like receptor-4, which in turn triggers NF-kB-mediated inflammation throughout the body. The review identifies several biomarkers linked to inflammation in metabolic disease as especially promising: circulating LBP, sCD14, zonulin, intestinal-type fatty-acid binding protein (I-FABP), occludin, diamine oxidase (DAO), and the urinary lactulose-to-mannitol ratio. These markers are not merely academic curiosities. Higher circulating sCD14 and LPS are prospectively associated with total mortality, incident coronary heart disease, and stroke in older adults, according to data cited in the review.

How Intestinal Permeability Raises Cardiovascular and Metabolic Disease Risk

The real-world stakes become clearest when the review examines specific disease populations. In type 2 diabetes patients, elevated LPS, zonulin, and I-FABP levels correlate positively with HbA1c, triglycerides, total cholesterol, TNF-alpha, and IL-6, meaning the gut barrier markers track closely with the classic signals of metabolic dysfunction. A separate body of prospective research confirms that elevated intestinal permeability biomarkers link to incident cardiovascular events such as myocardial infarction and stroke, even after adjusting for traditional cardiovascular risk factors. This positions leaky gut not as a downstream consequence of metabolic disease but as a plausible contributor to it, with gut barrier dysfunction documented in obesity and type 2 diabetes now drawing serious attention from cardiometabolic researchers.

One of the review's more striking observations concerns metabolically healthy obesity (MHO), a phenotype often assumed to be low-risk because standard metabolic markers appear normal. The MHO group and the metabolically unhealthy obesity (MUO) group both showed higher LBP and a higher LBP-to-sCD14 ratio compared with normal-weight controls. That finding suggests low-grade inflammation driven by intestinal permeability is already present in people with MHO, even before clinical metabolic dysfunction develops. By contrast, the normal-weight obesity (NWO) group showed no differences in gut integrity markers compared with other groups, a nuance the authors flag as warranting further investigation.

How Researchers Measure a Gut Barrier That Nobody Can See

Quantifying intestinal permeability has historically been awkward. The gold-standard approach involves administering an oral tracer solution containing lactulose and mannitol, then measuring how much of each molecule crosses the gut wall into urine. The ratio of the two reflects paracellular permeability, but collecting timed urine samples over several hours makes the test impractical for large epidemiological studies. Blood-based markers are a practical alternative: common methods for measuring intestinal permeability now include LBP, zonulin, I-FABP, and DAO assays, all of which can be run from a standard venous blood draw. The review argues that plasma LBP is currently the most promising single biomarker for widespread use across adult populations, while fecal zonulin shows particular potential in overweight and obese individuals.

The Shannon diversity index, a measure of gut microbiota richness, also appeared in the dataset: it was higher in normal-weight controls compared with the MUO group and inversely correlated with C-reactive protein (CRP). LBP itself showed strong and consistent relationships with CRP across the full sample and specifically within the MHO subgroup, reinforcing the idea that barrier disruption and systemic inflammation are tightly coupled.

Zonulin Reliability and the Limits of Cross-Sectional Data

The review is candid about where the field still has work to do. Most of the evidence linking intestinal permeability to cardiovascular disease is cross-sectional: researchers measured biomarkers and disease status at the same time, which makes it difficult to establish whether a leaky gut precedes disease or develops alongside it. More prospective cohort studies are needed to clarify the timeline. The call for better biomarkers is complicated by a known problem with one of the most widely used markers: commercial ELISAs for zonulin were built around a peptide sequence later found to be unrelated to the actual zonulin protein, raising serious questions about the reliability of published zonulin data. The field is actively working to standardize assays and validate replacements, but the issue means some zonulin-based findings should be interpreted with caution.

Therapeutic Targets: Fixing the Barrier to Treat the Disease

If a permeable gut drives inflammation that accelerates metabolic and cardiovascular disease, then repairing the barrier becomes a therapeutic target in its own right. The review points to emerging evidence that assessing intestinal permeability can offer insights into both disease severity and the efficacy of treatment. Clinical drugs already in widespread use, including metformin and berberine, have shown promise in improving metabolic disease progression by modulating the intestinal barrier. On the microbiome side, strategies such as prebiotics, probiotics, and synbiotics are being evaluated for their ability to strengthen gut barrier function and reduce cardiometabolic inflammation in people with metabolic conditions. Whether biomarkers like LBP or I-FABP could eventually serve as companion diagnostics, tracking whether a given intervention is actually tightening the gut barrier, remains an open and genuinely exciting question for the next generation of trials.